Evidence map›Paper›PMID 39764216›Full record

ArticleEXCLI journal2024

Fer-1 like family member 4 pseudogene: novel potential diagnostic and prognostic biomarker for cutaneous melanoma.

Tomasz Kolenda, Kacper Guglas, Maciej Stasiak, Paulina Poter, Joanna Kozlowska-Maslon, Piotr Bialas, Joanna Sobocinska, Marlena Janiczek-Polewska, Patrycja Mantaj, Anna Paszkowska and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EXCLI journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tomasz KolendaDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland.
Kacper GuglasLaboratory of Cancer Genetics, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
Maciej StasiakLaboratory of Cancer Genetics, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
Paulina PoterDepartment of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
Joanna Kozlowska-MaslonLaboratory of Cancer Genetics, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
Piotr BialasChair and Department of Cell Biology, Poznan University of Medical Sciences, 5D Rokietnicka, 60-806 Poznan, Poland.
Joanna SobocinskaLaboratory of Cancer Genetics, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
Marlena Janiczek-PolewskaDepartment of Clinical Oncology, Greater Poland Cancer Center, 61-866 Poznan, Poland.
Patrycja MantajGreater Poland Cancer Center, Radiation Protection Department Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
Anna PaszkowskaLaboratory of Cancer Genetics, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
Zefiryn CybulskiGreater Poland Cancer Center, Research and Implementation Unit, Garbary 15, 61-866 Poznan, Poland.
Anna TeresiakLaboratory of Cancer Genetics, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
Urszula KazimierczakDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland.
Anna PrzybylaDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland.
Andrzej MackiewiczDepartment of Cancer Immunology, Chair of Medical Biotechnology, Poznan University of Medical Sciences, 8 Rokietnicka Street, 60-806 Poznan, Poland.
Jacek MackiewiczDepartment of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous melanoma is the deadliest form of skin cancer. Despite advancements in treatment, many patients still face poor outcomes. A deeper understanding of the mechanisms involved in melanoma pathogenesis is crucial for improving diagnosis and therapy. Non-coding RNAs, with their extensive regulatory roles, show promise as diagnostic biomarkers. This study focuses on evaluating the

Indexed as

biomarkersBRAF mutationC20orf124FER1L4lncRNAmiR-128-3pmiR-330-5pmiR-514a-5pmiRNAnon-coding RNApseudogeneTCGA

Identifiers

PMID39764216
PMCPMC11701299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.